Hemodialysis autologous arteriovenous fistula in chronic kidney disease
Conditions
Interventions
A group:The first stage ( 1-12 weeks ) : Tongmai Xiaotong Decoction combined with stone ironing treatment
elution period ( 13-16 weeks ) : routine maintenance, dynamic information monitoring
the second stage ( 17-28 weeks ) : routine maintenance, dynamic information monitoring, non-intervention
B group:The first stage ( 1-12 weeks ) : routine maintenance, dynamic information monitoring, non-intervention
the second stage ( 17-28 weeks ) : Tongmai Xiaotong Decoction combined with stone ironing treatment.
Sponsors
Department of Nephrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? 1ESRD patients with regular hemodialysis = 3 months and stable condition ; ? 2 Patients aged 30-80 years old regardless of gender ? 3 Patients who were treated with AVF for dialysis each time which met the criteria for judging the maturity of AVF in the consensus of Chinese experts on vascular access for dialysis : good anastomotic tremor no abnormal enhancement weakening or disappearance straight fistula vein superficial easy to puncture uniform thickness and sufficient puncture area. The natural blood flow was > 500 ml / min the inner diameter of the puncture vein was = 5 mm and the depth from the skin was < 6 mm. ? 4 The dialysis program was regular hemodialysis 3 times a week and the arteriovenous puncture needles were 16 G and 17 G ; ? 5 The pump-controlled blood flow was 200-260 ml / min. ? 6 Volunteered to participate in the experiment and signed the informed consent.
Exclusion criteria
Exclusion criteria: ? 1 patients with drug allergy and intolerance of treatment technology in the prescription ; ? 2 patients with open skin damage or skin lesions in the treatment area ; ? 3 patients with arteriovenous fistula blood flow dysfunction ( stenosis, thrombosis, etc. ) or other serious complications requiring intervention ; ? 4 Unstable vital signs, or combined with a variety of important organ failure and immune diseases, as well as other serious systemic diseases, such as cirrhosis, blood system diseases and malignant tumors ; patients with bleeding tendency diseases ; ? 5 is participating in other clinical researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ultrasonic index; | — |
Secondary
| Measure | Time frame |
|---|---|
| fistula patency rate;Puncture pain assessment;rate of complications;High-sensitivity C-reactive protein, interleukin-6, vascular endothelial factor; | — |
Countries
China
Contacts
Public ContactLin-yang Li
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Outcome results
None listed